IL240557A0 - Formulations of laquinimod for transdermal administration - Google Patents

Formulations of laquinimod for transdermal administration

Info

Publication number
IL240557A0
IL240557A0 IL240557A IL24055715A IL240557A0 IL 240557 A0 IL240557 A0 IL 240557A0 IL 240557 A IL240557 A IL 240557A IL 24055715 A IL24055715 A IL 24055715A IL 240557 A0 IL240557 A0 IL 240557A0
Authority
IL
Israel
Prior art keywords
laquinimod
transdermal formulations
transdermal
formulations
Prior art date
Application number
IL240557A
Other languages
English (en)
Hebrew (he)
Inventor
Ralph Stefan
Tanja Pries
Hans-Juergen Mika
Dirk Schenk
Sabina Prohl
Original Assignee
Teva Pharma
Ralph Stefan
Tanja Pries
Mika Hans Juergen
Dirk Schenk
Sabina Prohl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Ralph Stefan, Tanja Pries, Mika Hans Juergen, Dirk Schenk, Sabina Prohl filed Critical Teva Pharma
Publication of IL240557A0 publication Critical patent/IL240557A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL240557A 2013-03-14 2015-08-13 Formulations of laquinimod for transdermal administration IL240557A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781585P 2013-03-14 2013-03-14
PCT/US2014/026807 WO2014152009A1 (en) 2013-03-14 2014-03-13 Transdermal formulations of laquinimod

Publications (1)

Publication Number Publication Date
IL240557A0 true IL240557A0 (en) 2015-10-29

Family

ID=50729775

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240557A IL240557A0 (en) 2013-03-14 2015-08-13 Formulations of laquinimod for transdermal administration

Country Status (8)

Country Link
US (1) US20160038435A1 (enExample)
EP (1) EP2968203A1 (enExample)
JP (1) JP2016513665A (enExample)
CA (1) CA2900977A1 (enExample)
HK (1) HK1220125A1 (enExample)
IL (1) IL240557A0 (enExample)
MX (1) MX2015010967A (enExample)
WO (1) WO2014152009A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2015138887A1 (en) * 2014-03-14 2015-09-17 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of laquinimod by oral patches
CN112656778A (zh) * 2020-12-28 2021-04-16 广东红珊瑚药业有限公司 一种压敏胶基质以及一种贴剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
RS53666B1 (sr) 2005-10-19 2015-04-30 Teva Pharmaceutical Industries Ltd Kristali lakvinimod natrijuma i proces za njihovo dobijanje
UA96449C2 (en) 2006-06-12 2011-11-10 Тева Фармасьютикл Индастриз, Лтд. Stable laquinimod preparations
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
BRPI0913518A2 (pt) 2008-09-03 2016-07-26 Teva Pharma composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune
WO2010147665A1 (en) 2009-06-19 2010-12-23 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
CA2769623A1 (en) 2009-07-30 2011-02-03 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
DE102010026879A1 (de) * 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
CN102781240A (zh) 2010-03-03 2012-11-14 泰华制药工业有限公司 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
BR112012022064A2 (pt) 2010-03-03 2015-09-08 Teva Pharma tratamento de artrite lúpica usando laquinimod
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
US8252993B1 (en) 2010-05-25 2012-08-28 Pioneer Hi-Bred International, Inc. Inbred maize variety PH18FN
MX2013000333A (es) 2010-07-09 2013-02-26 Teva Pharma N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
BR112013000607A2 (pt) 2010-07-09 2016-06-28 Teva Pharma 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações
KR20130124518A (ko) 2010-12-07 2013-11-14 테바 파마슈티컬 인더스트리즈 리미티드 다발경화증 환자의 피로를 감소시키고, 기능 상태를 개선시키고, 삶의 질을 개선시키기 위한 라퀴니모드의 용도

Also Published As

Publication number Publication date
MX2015010967A (es) 2015-10-26
JP2016513665A (ja) 2016-05-16
US20160038435A1 (en) 2016-02-11
WO2014152009A1 (en) 2014-09-25
HK1220125A1 (zh) 2017-04-28
CA2900977A1 (en) 2014-09-25
EP2968203A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
HUE061252T2 (hu) Lizinspecifikus demetiláz-1 inhibítorok
IL241101B (en) Medicinal uses of empagliflozin
ZA201506487B (en) Therapeutic compounds and compositions
IL241102A0 (en) Medicinal uses of empagliflozin
HUE045982T2 (hu) S-Ketamin-hidroklorid gyógyászati kompozíció
PL2981271T3 (pl) Zastosowania terapeutyczne empagliflozyny
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
ZA201604502B (en) Use of benzimidazole-proline derivatives
ZA201505830B (en) Formulations of organc compounds
ZA201602831B (en) Use of lactones
IL240763B (en) The halopyrazoles as thrombin inhibitors
IL245373A0 (en) Treatment of glaucoma by laquinimod
PL3063152T3 (pl) Dogodne wytwarzanie n-podstawionych morfinan-6-oli z morfinan-6-onów
IL240557A0 (en) Formulations of laquinimod for transdermal administration
ZA201600408B (en) Formulation of metaxalone
PL3071575T3 (pl) Wytwarzanie normorfinanów